Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2005-11-18
2009-12-08
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S009200, C435S004000, C436S063000, C436S064000
Reexamination Certificate
active
07628975
ABSTRACT:
The present invention provides methods, compositions and kits for discriminating between COX-1 and COX-2 activity. In particular, the prevent invention provides for the detection and/or measurement of COX-2 activity in subjects, samples thereof, and in laboratory tests. The present invention discloses that 2-arachidonylglycerol is a COX-2 selective substrate which is metabolized by COX-2 to prostaglandin glycerol esters (PG-Gs) and that the diversity of PG-Gs parallels that of arachidonic acid derived metabolites of COX. The present invention also provides certain novel COX-2 selective metabolites including prostaglandin I2-glycerol ester (PGI2-G) and 6-keto-prostaglandin F1α-glycerol ester. Methods and kits are described for detecting COX-2 activity comprising detecting PG-Gs (including the novel PG-Gs disclosed herein). Uses for these methods and kits include the detection and monitoring of inflammation and tumors or cancer. Additional uses include the monitoring of test agents in assays to screen for COX-2 specific inhibitors and other laboratory uses.
REFERENCES:
patent: 3632627 (1972-01-01), Gordon et al.
patent: 4675281 (1987-06-01), Lands et al.
patent: 5047354 (1991-09-01), Foegh et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5459239 (1995-10-01), O'Neill et al.
patent: 5474903 (1995-12-01), Huland
patent: 5475021 (1995-12-01), Marnett et al.
patent: 5543297 (1996-08-01), Cromlish et al.
patent: 5589575 (1996-12-01), Cohen et al.
patent: 5700654 (1997-12-01), Roberts et al.
patent: 5731343 (1998-03-01), Feng et al.
patent: 5756092 (1998-05-01), Michelet et al.
patent: 5837479 (1998-11-01), Young et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5858696 (1999-01-01), Roberts et al.
patent: 5874235 (1999-02-01), Chan et al.
patent: 5891622 (1999-04-01), Morrow et al.
patent: 5945675 (1999-08-01), Malins
patent: 5958978 (1999-09-01), Yamazaki et al.
patent: 5973191 (1999-10-01), Marnett et al.
patent: 5995645 (1999-11-01), Soenksen et al.
patent: 5999843 (1999-12-01), Anbar
patent: 6045773 (2000-04-01), Isakson et al.
patent: 6107049 (2000-08-01), Allard et al.
patent: 6207700 (2001-03-01), Kalgutkar et al.
patent: 71-125851 (1973-08-01), None
patent: 2155546 (1972-05-01), None
patent: 2159202 (1973-07-01), None
patent: WO 97/14679 (1997-04-01), None
patent: WO 98/50033 (1998-11-01), None
Haugland, Handbook of Fluorescent Probes and Research Products, Ninth Edition, 2002, p. 102.
Pace-Asciak, Prostaglandins, 1977, vol. 13, pp. 811-817.
Hamberg et al (Proceedings of the National Academy of Science, 1973, vol. 70, pp. 899-903).
Belvisi et al.; 1997; British Journal of Pharmacology; 120 (5), pp. 910-916.
Felder, et al.; 1998; Annu. Rev. Pharmacol. Tosicol.; vol. 38; pp. 179-200.
Futaki, et al.; Dec. 1997; Inflammation Research 46; pp. 496-502.
Freshney; The Culture of Animals; 1994; pp. 5 and 349-350.
Fritsche, et al.; The Journal of Pharmacology and Experimental Therapeutics; vol. 299; pp. 468-476, 2001.
Hamiltin, et al.; Oct. 1997; British Journal of Pharmacology; 122, proc. Suppl; pp. 22P.
Kalgutar, et al.; Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors; PNAS Jan. 18, 2000; 97(2) 925-930.
Kozak, et al.; Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2; The Journal of Biological Chemistry Oct. 27, 2000; 43:33744-33749.
Kozak, et al.; Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol; JBP Papers in Press Jun. 11, 2001.
Lands, et al.; Phospholipid precursors of prostaglandins; Biochem. Biophys. Acta 1968; 164:426-429.
Lapointe, et al.; Jan. 1998; Hypertension (Dallas); 31 1 part 2; pp. 218-224.
Prescott; A thematic series on oxidation of lipids as a source of messengers; J.Biol. Chem.; 274:22901, 1999.
Smith, et al.; Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and -2; The Journal of Biological Chemistry Dec. 27, 1996; 271:52:33157-33160.
So, et al.; The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation; J. Biol. Chem; 273:5801-5807, 1998.
Tanha, et al.; Optimal Design Features of Camelized Human Single-Domain Antibody Libraries; JBP Papers in Press May 2, 2001.
Tokumoto, et al.; Specificity of Prostagland D2 Binding to Synaptic Membrane Fraction of Rat Brain; Brain Research 1986; 362:114-121.
Tsujii et al.; Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential; Proc. Natl Acad. Sci. Apr. 1997; 94:3336-3340.
Vonkeman, et al.; The action of prostaglandin synthetase on 2-arachidonyl-lecithin; Biochem. Biophys. Acta; 164:430-432, 1968.
Woodward, et al.; The pharmacology of bimatoprost (Lumigan); Surv. Ophthalmol.; 45 Suppl 4; S337-345, 2001.
Yu, et al; Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2; The Journal of Biological Chemistry Aug. 22, 1997; 272(34):21181-21186.
Kozak Kevin R.
Marnett Lawrence J.
Canella Karen A
Myers, Jr. Richard S.
Stites & Harbison PLLC
Vanderbilt University
LandOfFree
Compositions and methods for detecting and quantifying COX-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for detecting and quantifying COX-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for detecting and quantifying COX-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096085